top of page

KAER's CEO Donovan B. Yeates will be a Keynote Speaker at 7th International Conference on PharmScience Research & Development 

 

Where:  San Francisco, CA, USA

When:   February 24-26, 2025

What We Do

KAER Biotherapeutics Corporation produces AeroPulsR and SUPRAER-Clinic to rapidly administer high doses of aerosol therapeutics to treat life-threatening respiratory disorders in clinical settings of NICU, PICU, ICU, emergency rooms and surgical suites.

The Challenge

In the USA, 5.7 million patients are admitted to ICU each year. Antibiotic aerosols are delivered to 2.5 million of these, of which 1.3 million are intubated.  Children up to 5 years of age and older adults are susceptible to respiratory distress and may need mechanical ventilation. 

The Reason

Inadequate deposition of aerosolized drug therapy in the distal lungs has been associated with unresolved bacterial and viral pneumonias, leading to respiratory insufficiency, failure and ultimately death.

Our Mission

KAER’s goal is to markedly decrease the mortality rate of 40% of patients with respiratory distress through efficacy achievement of inhaled antimicrobials and sufficient mass of the biophysical activity of surfactant to the distal lungs.

Our Expertise

AeroPulsR and SUPRAER-Clinic incorporate new aerosolization technology that generates aerosols of even high-viscosity drug solutions, delivering them at high concentrations. These aerosols may include antibiotic, antiviral, surfactant, biologic and oligomeric molecules, without degradation. 

Our Advanced Technology

AeroPulsR delivers aqueous aerosols at high concentrations to pediatric and adult patients by three distinct modes: (i) continuously, (ii) periodically (timed with inspiration), and (iii) spontaneously, with unsupported or CPAP-supported breathing. SUPRAER-Clinic delivers solid particle aerosols.

KAER for You

KAER, AeroPulsR delivers  aerosols of your API within the shortest period treatment to the respiratory tract, including the deep lung in pediatric and adult patients.

bottom of page